Oleg Kotelskiy, DO
Family Medicine · Brooklyn, NYNPI 1003871179
Payments from drug & device makers
Across 159 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$498
- Amarin Pharma, Inc.$440
- Novo Nordisk$428
- E.r. Squibb & Sons, L.L.C.$349
- Novartis$307
- Merck$237
- plus $967 from 14 others
What the payments were for
- Food & beverage$3,226100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $498 |
| Amarin Pharma, Inc. | 21 | $440 |
| Novo Nordisk | 21 | $428 |
| E.r. Squibb & Sons, L.L.C. | 18 | $349 |
| Novartis | 13 | $307 |
| Merck | 13 | $237 |
| Pfizer | 11 | $221 |
| Kowa Pharmaceuticals America, Inc. | 6 | $124 |
| Amgen | 5 | $116 |
| Lilly USA, LLC | 5 | $114 |
| AbbVie(2 entities) | 6 | $111 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $68 |
| Johnson & Johnson | 2 | $45 |
| Boehringer Ingelheim | 2 | $39 |
| Shield Therapeutics Inc | 1 | $25 |
| Ardelyx, Inc. | 1 | $25 |
| Ironwood Pharmaceuticals, Inc | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Vivus LLC | 1 | $13 |
How this compares
$3,226 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 324 | $124,532 |
| JardianceEmpagliflozin | 165 | $123,350 |
| EliquisApixaban | 195 | $122,769 |
| Diclofenac Sodium | 175 | $93,294 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 49 | $73,504 |
| JanumetSitagliptin Phos/Metformin Hcl | 86 | $69,987 |
| JanuviaSitagliptin Phosphate | 111 | $65,925 |
| LinzessLinaclotide | 97 | $50,933 |
| OzempicSemaglutide | 30 | $36,583 |
| CreonLipase/Protease/Amylase | 38 | $35,331 |
| FarxigaDapagliflozin Propanediol | 46 | $35,033 |
| EntrestoSacubitril/Valsartan | 37 | $26,412 |
| TrulicityDulaglutide | 20 | $22,626 |
| ZenpepLipase/Protease/Amylase | 17 | $21,140 |
| Dexlansoprazole DrDexlansoprazole | 114 | $19,272 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $39 | $144,081200 claims |
| MerckJanumet, Januvia, Belsomra | $237 | $141,231210 claims |
| PfizerEliquis | $221 | $122,769195 claims |
| AbbVieLinzess, Creon, Synthroid | $111 | $89,910193 claims |
| AstraZenecaFarxiga, Nexium | $498 | $38,65960 claims |
| Novo NordiskOzempic | $428 | $36,58330 claims |
| NovartisEntresto | $307 | $26,41237 claims |
| Lilly USA, LLCTrulicity | $114 | $22,62620 claims |
| Johnson & JohnsonXarelto, Invokana | $45 | $17,65634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Brooklyn
- Michael YuryevBrooklyn$589K
- Matthew SpitzerBrooklyn$469K
- Walford LindoBrooklyn$104K
- Fu Fu HeBrooklyn$101K
- Jonathan ChangBrooklyn$66K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.